ClinicalTrials.gov
ClinicalTrials.gov Menu

Fulvestrant With or Without Ganetespib in HR+ Breast Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01560416
Recruitment Status : Completed
First Posted : March 22, 2012
Results First Posted : January 3, 2019
Last Update Posted : January 3, 2019
Sponsor:
Information provided by (Responsible Party):
Nancy Lin, MD, Dana-Farber Cancer Institute

February 21, 2012
March 22, 2012
August 16, 2018
January 3, 2019
January 3, 2019
May 2012
June 2016   (Final data collection date for primary outcome measure)
Progression-Free Survival (PFS) [ Time Frame: Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles longer-term. Participants in this study cohort were followed for survival up to 4 years from treatment end. ]
PFS based on Kaplan-Meier is defined as the time from study entry to the earliest documentation of disease progression (PD) or death. Participants alive without evidence of PD are censored at the date of last disease assessment. Participants who receive non-protocol anti-cancer therapy before disease progression are censored at time of last disease assessment.
Effect of Adding Ganetespib to Fulvestrant [ Time Frame: 2 years ]
Evaluate the effect of the addition of ganetespib to fulvestrant on progression-free survival (PFS), compared to fulvestrant alone
Complete list of historical versions of study NCT01560416 on ClinicalTrials.gov Archive Site
  • Grade 3-4 Toxicity Rate [ Time Frame: AEs were assessed every cycle on treatment (weeks 2-3 on cycle 1). Median treatment duration was 4 cycles/~4 months on each arm. Maximum treatment duration was 41 cycles (Arm A) and 42 cycles (Arm B) which approximates 38 months. ]
    All grade 3-4 adverse events (AE) with treatment attribution of possibly, probably or definite based on NCI Common Toxicity Criteria for Adverse Events version 4 (CTCAEv4) as reported on case report forms were counted to calculate the percentage of participants experiencing at least one treatment-related grade 3 or 4 AE of any type on treatment.
  • Objective Response Rate (ORR) [ Time Frame: Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles thereafter on treatment. Maximum treatment duration was 41 cycles (Arm A) and 42 cycles (Arm B) which approximates 38 months. ]
    ORR was defined as the percentage of participants with measurable disease at baseline achieving complete response (CR) or partial response (PR) based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PR or better overall response assumes at a minimum incomplete response/stable disease (SD) for the evaluation of non-target lesions and absence of new lesions.
  • Clinical Benefit Rate (CBR) [ Time Frame: Disease was assessed radiographically every 2 cycles for year 1 and every 2-4 cycles thereafter on treatment. Maximum treatment duration was 41 cycles (Arm A) and 42 cycles (Arm B) which approximates 38 months. ]
    CBR was defined as the percentage of participants with measurable disease at baseline achieving complete response (CR), partial response (PR), or stable disease (SD) for 24 weeks or longer based on RECIST 1.1 criteria on treatment. Per RECIST 1.1 for target lesions: CR is complete disappearance of all target lesions and PR is at least a 30% decrease in the sum of longest diameter (LD) of target lesions, taking as reference baseline sum LD. PD is at least a 20% increase in sum LD of target lesions (smallest sum LD reference), new lesions, and/or unequivocal progression of existing non-target lesions. Stable disease (SD) is defined as any condition not meeting the above criteria. SD needed to be a minimum 24 weeks in duration.
  • Overall Survival (OS) [ Time Frame: Participants were followed long-term for survival every 3 months from the end of treatment until death, lost to follow-up or up to 4 years from treatment end. Median survival follow-up was 28 months for the study cohort. ]
    OS based on Kaplan-Meier is defined as the time from study entry to death or date last known alive or censored at date last known alive.
  • Number of participants with adverse events after treatment with Ganetespib Plus Fulvestrant [ Time Frame: 2 years ]
    To describe the grade and frequency of adverse events according to CTCAE v 4.0 in patients treated with ganetespib in combination with fulvestrant and in patients treated with fulvestrant alone
  • Objective Response Rate Between Arms by RECIST [ Time Frame: 2 years ]
    To describe and compare the objective response rate by RECIST 1.1 between arms, limited to patients with measurable disease at baseline
  • Comparison of Clinical Benefit Rate Between Arms [ Time Frame: 2 years ]
    To describe and compare the clinical benefit rate, defined as complete response (CR)+partial response (PR)+stable disease >/= 6 months between arms
  • Comparison of Overall Survival Between Arms [ Time Frame: 2 years ]
    To describe and compare overall survival (OS) between arms
Not Provided
Not Provided
 
Fulvestrant With or Without Ganetespib in HR+ Breast Cancer
Randomized Phase II Study of Fulvestrant With or Without Ganetespib in Patients With Hormone Receptor-Positive, Metastatic Breast Cancer

Ganetespib is a drug that may stop cancer cells from growing. This drug has been used in other research studies and laboratory experiments. It has also been studied in phase I trials, where the appropriate dosing has been determined. Ganetespib is considered an "HSP90 inhibitor". By blocking HSP90, ganetespib is thought to reduce the ability of cancer cells to become resistant to treatment.

Fulvestrant is a hormonal therapy that works by attaching to estrogen receptors. In doing so, it can block the effect of estrogen on cancer cells. In addition, fulvestrant causes a decrease in the number of estrogen receptors. Fulvestrant is a drug that is approved by the FDA for treatment of metastatic, hormone receptor positive breast cancer, based upon the results of phase III clinical trials.

In the laboratory, adding ganetespib to fulvestrant appears to improve its effectiveness. It is not known whether this is true in humans. In this research study, we are evaluating the effect of the addition of ganetespib to fulvestrant in participants with hormone receptor-positive, metastatic breast cancer.

Because no one knows which of the study options is best, you will be "randomized" into one of the study groups: Arm A: Fulvestrant or Arm B: Fulvestrant plus Ganetespib. You will have a one-third chance of being placed in Arm A and a two-thirds chance of being placed in Arm B.

If you are initially placed in Arm A but your disease progresses, you will have the option of receiving the combination of fulvestrant plus ganetespib as part of Arm C.

You will undergo the following procedures during the research study: study drug(s), blood tests, clinical exams and scans/imaging tests.

Interventional
Phase 2
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Participants were randomized 2:1 B Fulvestrant+Ganetespib:A Fulvestrant
Masking: None (Open Label)
Primary Purpose: Treatment
Breast Cancer
  • Drug: Fulvestrant
    Other Name: Faslodex
  • Drug: Ganetespib
    Other Name: STA9090
  • Active Comparator: ARM A - Fulvestrant
    Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Eligible participants on Arm A were allowed to crossover to Arm B upon disease progression. Treatment continued for Arm A participants until 2nd disease progression.
    Intervention: Drug: Fulvestrant
  • Active Comparator: Arm B - Fulvestrant+Ganetespib

    Fulvestrant: 500 mg administered by intramuscular injection on days 1 and 15 of cycle 1, day 1 of cycle 2 and each subsequent cycle; cycle duration is 28 days Ganetespib: 200 mg/m2 administered intravenously on days 1, 8 and 15 of each 28 day cycle

    Arm B participants whose disease was at a minimum stable could elect to discontinue ganetespib after 6 cycles or stay on combination treatment until disease progression. Otherwise, Arm B participants taken off ganetespib for toxicity were to remain on single agent fulvestrant until disease progression.

    Interventions:
    • Drug: Fulvestrant
    • Drug: Ganetespib
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
50
71
June 2016
June 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Histologically confirmed invasive breast cancer that is metastatic or unresectable locally advanced
  • Estrogen and/or progesterone receptor positive breast cancer
  • HER2 negative
  • Measurable disease is required (effective 4/30/14: all non-measurable [evaluable] disease slots have been filled)
  • Endocrine resistant breast cancer
  • May have received up to one prior line of chemotherapy for metastatic or unresectable locally advanced breast cancer
  • May have initiated bisphosphonate therapy prior to start of protocol therapy
  • Must be at least 2 weeks from prior chemotherapy or radiotherapy
  • ECOG performance status of 0 or 1
  • Availability of tissue block from initial breast cancer diagnosis and/or metastatic recurrence
  • For subjects with biopsy-accessible disease, must be willing to undergo a required on-treatment research biopsy
  • Adequate IV access

Exclusion Criteria:

  • Pregnant or breastfeeding
  • Prior treatment with HSP90 inhibitor
  • Prior treatment with fulvestrant
  • Concurrent treatment with commercial agents or other agents with the intent to treat the participant's malignancy
  • Untreated or progressive brain metastases
  • Pending visceral crisis, in the opinion of the treating investigator
  • History of allergic reactions attributed to compounds of similar chemical or biologic composition to fulvestrant or ganetespib
  • Uncontrolled intercurrent illness
  • Other malignancies within 3 years
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT01560416
11-477
Yes
Not Provided
Not Provided
Nancy Lin, MD, Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Not Provided
Principal Investigator: Nancy U Lin, MD Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
December 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP